A tumor microenvironment acid-responsive therapy combining fenton chemistry and chemotherapy via TNF pathway for synergistic and safe lung cancer treatment Authors: Cai Zhang, Long Zhang, Jing Tian, Jie Shi, Xiao Li, Tong Jiao, Xin Zhao, Bo Yuan, Lizhong Zeng, Yuanyuan Cheng, Umid Sunnatovich Mamedov, Laziz Nurkhonovich Niyazov, Shuanying Yang Published: 2026 ABSTRACT AbstractLung cancer is one of the most common malignant tumors, but traditional treatments, particularly chemotherapy, often face significant challenges, including drug resistance and high systemic toxicity. In this study, we developed a novel acid responsive nanoparticle, La₂O₃@PDA/PTX, by combining lanthanum oxide (La₂O₃), polydopamine (PDA), and paclitaxel (PTX). This nanoparticle demonstrated excellent aqueous stability, high biocompatibility, and low toxicity. Benefiting from its structural design, the nanoparticle enables targeted delivery of PTX while simultaneously elevating intracellular reactive oxygen species (ROS) levels, which synergistically exacerbates oxidative stress injury within tumor cells. Mechanistically, La₂O₃@PDA/PTX inhibited tumor growth and induced apoptosis by increasing intracellular ROS, inducing G2/M cell-cycle arrest, and regulating proliferation and apoptosis related proteins, including Ki67, Bcl-2, and Bax. At the signaling level, La₂O₃@PDA/PTX increased NF-κB p65 phosphorylation and modulated TNF/NF-κB associated signaling, accompanied by changes in tumor associated cytokines and T-cell associated immunofluorescence signals. Furthermore, it effectively inhibited the progression of both subcutaneous and metastatic tumors with no significant adverse effects on major organs or peripheral blood parameters, showing great promise for future translational research. Collectively, this work presents an acid responsive therapeutic strategy combining ROS enhancement, chemotherapy, and TNF/NF-κB associated signaling modulation for lung cancer treatment. Graphical Abstract Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12951-026-04932-y.Keywords: Cancer therapy, Paclitaxel, ROS, Cell cycle, Lanthanum Introduction With the incidence and mortality of cancer rising, malignant tumors have become a global issue, and among them, lung cancer is one of the most common and deadliest. According to Global Cancer Statistics 2022, there were an estimated 2.5 million new lung cancer cases worldwide in 2022, accounting for 12.4% of all new cancer cases. Meanwhile, lung cancer was the leading cause of cancer related death worldwide, with an estimated 1.8 million deaths [1]. In the past three decades, because of remarkable advances in surgery, chemotherapy, radiotherapy, molecular targeted therapy, and immunotherapy, the diagnosis and treatment of lung cancer have made significant progress. However, since most lung cancer patients are diagnosed at an advanced stage, the unfavorable prognosis remains prevalent [2, 3]. Consequently, there is an urgent need to find more innovative paradigms for lung cancer patients aimed at mortality reduction. Paclitaxel (PTX), a representative plant derived chemotherapeutic agent, has been widely used in the treatment of malignant tumors, including lung cancer, breast cancer, pancreatic cancer, and other cancers [4, 5]. For patients with advanced lung cancer who are ineligible for surgery, targeted therapy or immunotherapy may be preferred when appropriate; however, not all patients harbor actionable mutations or meet the eligibility criteria for these treatments. Therefore, chemotherapy, represented by paclitaxel (PTX) and platinum based agents, remains the mainstay of lung cancer therapy [6]. PTX promotes microtubule stabilization by specifically binding to β-tubulin, thereby disrupting mitosis, inducing G2/M cell-cycle arrest, and triggering apoptosis [4, 7]. However, its clinical utility often faces limitations such as water insolubility, systemic toxicity, and drug resistance [8, 9]. In recent years, with the rapid development of biomaterials, novel nanocarriers have been used to enhance drug delivery efficiency and minimize adverse reactions, such as nab-PTX [10, 11]. Although existing commercial formulations have achieved remarkable success in clinical settings, PTX formulations still face several issues such as low utilization and off-target toxicity [4]. Thus, novel nano-drug delivery platforms that can significantly reduce PTX toxicity and enhance its therapeutic efficacy still need to be explored. To improve the application of nano-drug delivery platforms, researchers have explored various approaches to optimize materials. Among these approaches, metal nanomaterials have attracted wide attention. Previous studies have shown that metal nanomaterials can minimize drug related side effects and further enhance anticancer efficacy by triggering chemodynamic therapy (CDT) [12–15]. CDT can kill cancer cells by generating highly toxic hydroxyl radicals (·OH) through Fenton or Fenton-like reactions in an acidic and H2O2 overproduced tumor microenvironment (TME) [16, 17]. In tumor cells, to maintain rapid proliferation, metabolic reprogramming often occurs, enhancing glucose uptake, and then it will be transformed into lactic acid by glycolysis. This phenomenon is known as the “Warburg effect” [18–20]. Excessive lactic acid production leads to TME remodeling, which can affect immune cell infiltration and influence tumor initiation and progression [21, 22]. In acidic conditions, Fenton and Fenton-like reactions between transition metal ions (such as Fe, Co, Ni, Cu, Mn and Zn [23]) and H₂O₂ are the representative pathways for CDT [16, 24]. For example, iron containing nanomaterials can release ferrous ions in tumor cells and trigger the Fenton or Fenton-like reactions under acidic conditions, which will lead to tumor cell death [24, 25]. However, in the TME, Fenton and Fenton-like reactions are often inhibited, because of the limitations of H₂O₂ availability [26]. To overcome this limitation, researchers have developed various inorganic peroxide nanomaterials with TME responsive and H₂O₂ release properties to enhance Fenton/Fenton-like reactions [27]. For example, Liu et al. synthesized a temperature responsive CaO₂ nanomaterial that can rapidly generate H₂O₂ in acidic conditions and enhance the Fenton reaction involving Mn²⁺ [28]. In addition to the antitumor effects of CDT itself, combining CDT reagents with chemotherapy drugs often results in improved antitumor activity [29]. In several studies involving doxorubicin (DOX), researchers combined DOX based chemotherapy with nanomaterial mediated CDT to kill tumor cells through multiple mechanisms and reduce drug resistance [30–32]. Furthermore, researchers have proposed some strategies which combine cisplatin or carboplatin with CDT for cancer treatment [33, 34]. Additionally, researchers have demonstrated that cisplatin can activate nicotinamide adenine dinucleotide phosphate oxidase (NOX) in tumor cells, leading to the production of H2O2, which enhances the antitumor effects of CDT [33]. Overall, combining nanomaterials with chemotherapeutic agents is a feasible approach to enhance anticancer efficacy and reduce drug resistance. In this study, we report a novel nanodrug delivery platform that uses lanthanum oxide (La₂O₃), a rare earth oxide, in combination with paclitaxel (PTX) to reduce side effects and enhance the efficacy of cancer chemotherapy (Fig. 1). La₂O₃ not only possesses excellent physicochemical stability and biocompatibility but also exhibits ROS enhancing biological effects after cellular internalization, including increased intracellular ROS, disruption of glutathione homeostasis, DNA damage, and apoptosis [35-37]. To integrate La₂O₃ mediated ROS enhancement with PTX delivery, a nanoscale PDA coating was formed on La₂O₃ through the oxidative self-polymerization of dopamine. The PDA layer provided binding sites for PTX and supported pH-responsive drug release under acidic conditions [38]. Through this mechanism, a dual anticancer effect combining chemotherapy and ROS enhancement can be achieved in synergy with the microtubule-stabilizing effect of PTX. Beyond these direct therapeutic effects, TNF/NF-κB associated signaling has been implicated in tumor progression and cellular responses to chemotherapy [39, 40]. We therefore further examined its potential involvement in the antitumor effects of La₂O₃@PDA/PTX. Schematic illustration of the construction of a La2O3-mediated nanoparticle paclitaxel delivery system and its application in lung cancer treatment. (A) In vitro synthesis of La2O3 nanoparticles and their assembly with polydopamine and paclitaxel to construct NP nanocomplexes. (B) Treatment of subcutaneous tumors and lung metastatic tumors in mice induced by LLC cells and Luc-MC38 cells via tail vein injection of La2O3@PDA/PTX. (C) La2O3 modulates the TNF/NF-κB associated signaling, increases intracellular ROS, and regulates the cell cycle, promoting T cell infiltration and tumor cell apoptosis. (D) La2O3@PDA/PTX releases from the bloodstream, regulating gene expression through the TNF/NF-κB associated signaling and generating reactive oxygen species to participate in tumor treatment Owing to the intrinsic photothermal properties of PDA, this platform may also be extended tophotothermal combination therapy in future studies [41]. Overall, this delivery system shows exceptional potential for future research on drug resistance, new drug development, and translational studies. Materials and methods Fabrication of La2O3@PDA/PTX Nanoparticles La(NO3)3·6H2O powder was dissolved in water and stirred vigorously to obtain a clear solution. Then, cetyltrimethylammonium bromide (CTAB) was added, and stirred at 180 °C for 12 h, followed by centrifugal washing and calcination at 500 °C for 6 h to obtain La2O3. Next, dopamine (DA) was added and stirred at room temperature for 2 h to form polydopamine (PDA), which spontaneously coated the surface of La₂O₃. Finally, PTX was incorporated and stirred for 12 h to enable its binding to PDA by hydrogen bonding, forming La₂O₃@PDA/PTX. The morphology of La₂O₃@PDA/PTX was characterized by TEM (JEOL, Japan). The diffraction pattern was characterized by X-ray diffraction (XRD, Rigaku, Japan) with a scanning range of 20°–90° and the scanning speed is 2°/min. The Fourier-transform infrared (FTIR) spectra of La₂O₃@PDA/PTX were analyzed by the spectrometer (Thermo Fisher, Nicolet iS10, USA). The hydrodynamic diameter and polydispersity index of La₂O₃@PDA/PTX, as well as the zeta potentials of La₂O₃, La₂O₃@PDA, and La₂O₃@PDA/PTX, were measured using a nanoparticle size and zeta potential analyzer. Additionally, the nanoparticle powder was dispersed in methanol, which was then sonicated for 10 min to dissolve the loaded PTX in NPS [42]. The amount of PTX was further measured by a ultraviolet-visible (UV-Vis) spectrophotometer at 227 nm [43, 44]. The drug encapsulation efficiency (EE) and drug load (DL) was calculated according to the following equations: To evaluate pH-dependent PTX release, La₂O₃@PDA/PTX was incubated in release media at pH 7.4, 6.3, and 5.4 at 37 °C. Samples were collected at predetermined time points (0, 3, 6, 12, 24, and 36 h), and the released PTX was quantified by high performance liquid chromatography (HPLC). Cumulative PTX release was calculated relative to the total amount of PTX loaded in the nanoparticles. Biocompatibility, safety and cytotoxicity of La2O3@PDA/PTX Red blood cells were used to evaluate the hemolytic property of La₂O₃@PDA/PTX (referred to as NPS). Briefly, 1 mL NPS, PTX and La₂O₃ were co-cultured with 20µL of RBCs in a culture plate. PBS solution and ultrapure water (ddH₂O) were used as negative and positive controls. After incubation at 37 °C for 3 h, the cell suspensions were collected to evaluate hemolysis of the red blood cells [45, 46]. Mouse fibroblast L929 cells, human lung cancer A549 cells, mouse lung cancer LLC cells, and mouse colon cancer MC38 cells were used to detect the cytotoxicity of NPS. In summary, L929, A549, LLC, and MC38 cells were seeded in 96-well plates, about 7,000 cells per well, and cultured in high-glucose DMEM medium with 10% FBS for 24 h. When the cells reached 70% confluence, the culture medium was replaced with fresh DMEM containing various concentrations of NPS, PTX, or La2O3 (0, 0.5, 1, 2, 4, 6, 8, 10 µg/mL). After 24 h of culture, cell viability was measured by CCK-8 (CCK8, TargetMol, C0005) at 450 nm. In addition, the cytotoxicity of NPS was reconfirmed by live/dead staining which added Calcein-AM and propidium iodide (PI) to the 96-well plates. After 30 min, the fluorescence signals were measured using 488 nm and 530 nm filters. Meanwhile, cells that were treated with NPS for 48 h were also assessed by CCK8. Apoptosis and proliferation assays Placed L929, A549, LLC, and MC38 cells in 6-well plates and cultured for 24 h. Then, the medium was replaced by fresh DMEM medium containing or lacking NPS, PTX or La2O3. The cells were then cultured for an additional 24 h. After that, detached the cells with 0.25% trypsin (1×) without EDTA, and analyzed for cell apoptosis by cell flow cytometry. In parallel, A549 and LLC cells were seeded in 12-well plates. After 24 h, the medium was replaced with fresh DMEM containing or not containing NPS, PTX, or La2O3 followed by another 24-hour incubation. Subsequently, cells were incubated with EdU for 2 h, fixed with 1mL of 4% paraformaldehyde, and permeated with 0.3% Triton X-100. The subsequent steps involved processing with the EdU-488 Cell Proliferation Kit (BeyoClick™ EdU Cell Proliferation Kit with Alexa Fluor 488, Beyotime, C0071S) and counterstaining the nuclei with Hoechst (TargetMol, C0164). Cell scratch and transwell migration assays Placed A549, LLC, and MC38 cells in 6-well plates, when the cells reached the appropriate confluence, a sterile 200 µL pipette tip was used to make a cell scratch. Subsequently, each group was added to DMEM medium containing 1% FBS, with or without 8 µg/mL NPS. Images of the scratch were recorded at 0, 12, 24, and 48 h using a microscope, with each time point in a separate well plate. Separately, cells (30,000 per well) were placed in the upper wells of transwell plates using DMEM medium without FBS. The lower wells were filled with DMEM containing 10% FBS, with or without 8 µg/mL NPS. After 24 h, the cells were treated with crystal violet and cell migration was observed and recorded using a microscope. Cell cycle and intracellular ROS detection A549 and LLC cells were cultured in 6-well plates for 24 h, then incubated in DMEM medium containing or lacking NPS, PTX or La2O3 for an additional 24 h. Then, cells were harvested and fixed in 75% ethanol for 12 h and stained with propidium iodide (PI). After that, the cell cycle was analyzed by flow cytometry. Separately, the cells in another group of 6-well plates were treated with the DCFH-DA and measured the ROS levels by flow cytometry. Construction of the cDNA library and RNA sequencing LLC cells cultured in DMEM medium without NPS as the control group, while LLC cells cultured in DMEM medium containing NPS were considered as the experimental group. Each group contained three biological replicates. The total RNA isolation, sequencing library preparation, and RNA sequencing were conducted by Beijing Nuohe Zhiyuan Biology Information Technology Co. RT-qPCR detection Total RNA from LLC cells was extracted using Trizol reagent kit. Quantitative primers of Cxcl1, Ccl20, Cxcl2, Lif, Ccl2, Ptgs2, Mmp9, Vcam1, Rhbdf2, Bcl2, Bax, and Ki-67 were designed by Sangon Biotech (Shanghai) Co., Ltd. GAPDH was used as an internal control, and the relative expression of Cxcl1, Ccl20, Cxcl2, Lif, Ccl2, Ptgs2, Mmp9, Vcam1, Rhbdf2, Bcl2, Bax, and Ki-67 were analyzed using the 2−ΔΔCt method. Western blotting and immunofluorescence LLC cells were seeded in 6-well plates and cultured for 24 h in medium with or without NPS. Primary antibodies, VCAM1 (Zenbio, 381014), PTGS2 (Proteintech, 12375-1-AP), MMP-9 (Proteintech, 10375-2-AP), Lif (Proteintech, 26757-1-AP), Bcl2 (Proteintech, 26593-1-AP) or Bax (Proteintech, 60267-1-Ig), Phospho-NF-κB p65 (Ser536, Proteintech, 80379-2-RR), NF-κB p65 (Proteintech, 80979-1-RR) and IκBα (zenbio, R380682). Goat Anti-Rabbit IgG(H + L) (SA00001-2) or Goat Anti-Mouse IgG(H + L) (Proteintech, SA00001-1) were used as the corresponding secondary antibodies. Meanwhile, LLC cells were seeded in 24-well plates and immunofluorescence staining was performed using the primary antibodies described above, together with Ki-67 (Proteintech, 28074-1-AP). Goat anti-rabbit IgG (H&L)-AcalephFluor 594 (Cohesion, CSA3611) and goat anti-mouse IgG (H&L)-AcalephFluor 488 (Cohesion, CSA3208) were used as the corresponding fluorescent secondary antibodies. For immunohistochemical analysis of ROS-associated oxidative damage, paraffin-embedded tumor sections were stained with primary antibodies against 4-hydroxynonenal (4-HNE, MCE, HY-P81208) and 8-hydroxy-2′-deoxyguanosine (8-OHdG, MCE, HY-P81140). Animal experiment Aged eight weeks C57BL/6 mice were purchased from the Experimental Animal Center of Xi’an Jiaotong University, Xi’an, China. Mice were placed under standard conditions of room temperature and dark/light cycle with sufficient food and water. All procedures were approved by the Institutional Ethics Committee of Xi’an Jiaotong University (No.:2024–2585) and conducted according to the Guidelines for the Institutional Animal Care and Use Committee of Xi’an Jiaotong University. Antitumor effect of La2O3@PDA/PTX in subcutaneous tumor model 100 µL LLC cells (5 × 10^6/mL) were subcutaneously injected to C57BL/6 mice to establish a subcutaneous tumor model. After 7 days of subcutaneous injection of tumor cells, the mice with subcutaneous tumors were randomly divided into four groups: the PBS group (injected with PBS), the NPS group (injected with NPS), the PTX group (injected with PTX), and the La group (injected with La2O3). Mice were injected with PBS, NPS, PTX or La2O3 through the caudal vein every two days for 4 times. During this period, the body weight and tumor volume of the mice were carefully measured and recorded. Calculated the tumoral volume following this formula: 1/2 of perpendicular length times to square width in cubic millimeters. Then, the blood and major organs were collected for routine blood tests, ELISA, hematoxylin-eosin (H&E), immunofluorescence staining and Immunohistochemistry. Antitumor effect of La2O3@PDA/PTX in lung metastatic tumor model Luciferase-labeled MC38 cells (Luc-MC38; 100 µL cell suspension at a concentration of 8 × 10⁶ cells/mL, equivalent to 8 × 10⁵ cells per mouse) were injected into C57BL/6 mice via tail vein to construct a murine lung metastasis model. On day 5 after tumor cell injection, bioluminescence imaging was performed to confirm pulmonary metastasis. The mice were then randomly assigned to the PBS and NPS groups, and intravenous treatment with PBS or NPS was initiated and repeated every 2 days until day 13. Follow-up bioluminescence imaging was performed on days 9 and 13 after administration of D-luciferin potassium salt using a PerkinElmer small animal imaging system. On day 15, serum samples were collected for biochemical measurements of ALT, AST, BUN, and creatinine. Lung tissues were subsequently collected, fixed, and embedded in paraffin for H&E staining, immunofluorescence staining, and immunohistochemistry. Metastatic burden was quantified from whole lung H&E sections as the metastatic tumor area relative to the total lung tissue area. Statistical analysis All statistical results in this study were processed using GraphPad Prism version 10.1.2 for Windows and analyzed by means ± standard deviation. Unpaired two-tailed Student’s t-test was used for comparison between two groups, and analysis of variance (ANOVA) was used for comparison between multiple groups. A P value of < 0.05 was considered statistically significant. Results Characteristics and characterization of La₂O₃@PDA/PTX The XRD pattern of the prepared La₂O₃ is shown in Fig. 2A, and the observed diffraction peaks corresponded to the characteristic peaks of La₂O₃. Figure 2B showed the FT-IR spectra of the prepared nanomaterials. From top to bottom, we observed a peak at 600–700 cm⁻¹ for La₂O₃, corresponding to the bending vibration of the La-O bond. In PDA, the peak at 3200–3500 cm⁻¹ can correspond to the stretching vibration of O-H and N-H, while the peak at 1600–1650 cm⁻¹ is related to the C = C aromatic ring stretching vibration. The peak at 1500–1550 cm⁻¹ corresponds to the N-H bending vibration, and those at 1200–1300 cm⁻¹ and 1000–1100 cm⁻¹ are attributed to the C-O and C-N stretching vibrations, respectively. In PTX, the peak at 3200–3500 cm⁻¹ is attributed to the O-H and N-H stretching vibration, and the peak at 1700–1750 cm⁻¹ corresponds to the C = O stretching vibration, which is one of the characteristic features of PTX. The peaks at 1600–1650 cm⁻¹, 1200–1300 cm⁻¹, and 1000–1100 cm⁻¹ correspond to the C = C aromatic ring stretching vibration, C-O stretching vibration, and C-N stretching vibration. The peak in the range of 700–900 cm⁻¹ corresponds to the out-of-plane C-H bending vibration of the aromatic ring, which is another characteristic feature of PTX. For La₂O₃@PDA/PTX, its FT-IR spectrum includes the characteristic peaks of La₂O₃, PDA, and PTX, indicating that we successfully formed La₂O₃@PDA/PTX. Physicochemical characterization, pH dependent PTX release, and hemocompatibility of La₂O₃@PDA/PTX. (A) XRD patterns of La2O3. (B) FTIR spectra of La2O3, La2O3@PDA and La2O3@PDA/PTX. (C) Zeta potentials of La2O3, La₂O₃@PDA, and La₂O₃@PDA/PTX. (D) TEM images of La2O3, La2O3@PDA and La2O3@PDA/PTX. (E) Intensity-weighted hydrodynamic size distribution and polydispersity index of La₂O₃@PDA/PTX. (F) Cumulative PTX release profiles at pH 7.4, 6.3, and 5.4. (G) Representative photographs and quantitative analysis of hemolysis after mouse erythrocytes were incubated with PBS, La₂O₃, PTX, La₂O₃@PDA/PTX, or ddH₂O for 3 h. (H) Representative microscopic images of erythrocytes following the indicated treatments Zeta-potential analysis further demonstrated changes in surface properties during the stepwise construction of the nanoparticles (Fig. 2C). The zeta potential shifted from approximately + 44 mV for La₂O₃ to approximately − 6 mV after PDA coating and further to approximately − 20 mV following PTX loading. This progressive change was consistent with PDA surface modification and subsequent PTX incorporation. TEM images showed that La₂O₃, La₂O₃@PDA, and La₂O₃@PDA/PTX retained a rod like morphology, with dry state particle dimensions of approximately 100–200 nm (Fig. 2D). DLS analysis showed an intensity weighted hydrodynamic diameter of approximately 341.7 nm and a PDI of 0.254 for La₂O₃@PDA/PTX, indicating acceptable dispersion uniformity in aqueous solution (Fig. 2E). The PTX encapsulation efficiency was 42.65% ± 2.05%, and the drug loading content was 8.53% ± 0.41%. The PTX release profiles exhibited an initial release phase followed by slower sustained release at all tested pH values (Fig. 2F). Cumulative PTX release increased as the pH decreased, with the lowest release observed at pH 7.4 and the highest at pH 5.4, supporting the pH-responsive release behavior of La₂O₃@PDA/PTX. Collectively, these results confirmed the successful construction of rod-shaped La₂O₃@PDA/PTX with stepwise surface modification, PTX loading, acceptable aqueous dispersion, and pH-responsive drug release. La₂O₃@PDA/PTX exhibits good safety and biocompatibility with strong cytotoxicity against tumor cells To evaluate the hemolytic property of La₂O₃@PDA/PTX (referred to as NPS hereafter), red blood cells (RBCs) were incubated with NPS and ddH₂O. After centrifugation, there was no hemolysis phenomenon observed in the NPS treated group (the supernatant was clear and colorless), whereas obvious hemolysis was observed in the control group treated with ddH₂O (Fig. 2G). Under the microscope, RBCs in the NPS treated group were observed intact and no signs of rupture, compared with ddH2O group (Fig. 2H). The hemolysis rate showed the NPS had extremely low hemolysis (Fig. 2G). Here, the PBS treated group was set as the baseline (0% hemolysis). These results demonstrate that NPS possesses excellent blood compatibility. We evaluated the safety and antitumor activity of different concentrations of NPS in mouse fibroblast L929 cells and A549, LLC, and MC38 tumor cells, and compared the effects of NPS with PTX and La₂O₃ (referred to as La) at the same drug concentrations. Live/dead staining indicated that, at NPS concentrations of 0–8 µg/mL, NPS showed no obvious cytotoxicity toward L929 cells; its cytotoxicity was much lower than that of PTX at the same concentrations and was comparable to that observed in the La group. Meanwhile, NPS exhibited significant anti-tumor activity in A549, LLC, and MC38 tumor cells (Fig. 3A), and demonstrated greater antitumor activity than PTX and La at the same concentration in A549 and LLC cells (Figure S1A). In addition, the cell proliferation assay (CCK-8) results also supported the conclusion, showing that after 24 and 48 h of treatment, the cytotoxicity of NPS was lower than that of PTX, whereas La exhibited effects similar to those of NPS (Fig. 3B and Figure S1B). Moreover, NPS exhibited strong broad-spectrum anti-tumor effects in A549, LLC, and MC38 cells (Fig. 3C), and was significantly higher than PTX and La at the same concentration after 24 h treatment (Figure S1C, D). These results suggest that La₂O₃@PDA/PTX has a favorable safety profile against non-tumor cells while inhibiting tumor cell growth. La₂O₃@PDA/PTX exhibits safety and cytocompatibility in vitro while inhibiting tumor cell growth and migration. (A) Biocompatibility and cytotoxicity assays of different concentrations of NPS and PTX (0–10 µg/mL) in L929, A549, LLC, and MC38 cells by Live/Dead staining. (B) CCK-8 assay of L929 cells after 24 h and 48 h treatment with NPS and PTX (0–10 µg/mL). (C) CCK-8 assay of A549, LLC, and MC38 cells after 24 h and 48 h treatment with NPS (0–10 µg/mL). (D) After treatment with NPS, La, and PTX, A549, and LLC cells were collected for apoptosis detection by flow cytometry, and quantitative analysis showing the apoptosis rate of A549 and LLC cells (E). (F) Cell scratch images of A549 and LLC cells (G) after 0, 12, 24 and 48 h treatment with NPS. (H) Images of transwell migration assay verifying tumor cells migration after NPS treatment for 24 h. (ns stands for no significant difference). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 La₂O₃@PDA/PTX demonstrates good safety and antitumor properties in vitro To further explore the antitumor activity and safety of NPS, we used flow cytometry to detect the apoptotic effects of NPS on L929, A549, and LLC cells. The results showed that, at an NPS concentration of 8 µg/mL, NPS had almost no cytotoxic effect on L929 cells. In contrast, the PTX group exhibited significant toxicity to L929 cells (Figure S2A, B). Furthermore, compared to the control group, NPS exhibited a stronger performance in tumor cell apoptosis (Fig. 3D, E). To confirm the general pro-apoptotic effect of NPS, we further tested it in MC38 cells. The results indicated that, beyond lung cancer cells, NPS also has a strong effect in tumor cell apoptosis on other tumor cells (Figure S2C, D). Moreover, the results of cell scratch (Fig. 3F, G and Figure S2E-H), with each time point in a separate well plate, and Transwell migration assays (Fig. 3H and Figure S2I) demonstrated that NPS could effectively inhibit the migration of tumor cells in vitro. In summary, under the condition of ensuring safety, La₂O₃@PDA/PTX was able to effectively promote cell apoptosis and inhibit tumor cell migration in vitro. La₂O₃@PDA/PTX inhibits tumor growth by suppressing proliferation, inducing cell cycle arrest, and increasing intracellular ros levels To further confirm the function of NPS in tumor proliferation, we performed an EdU assay on NPS treated A549 (Fig. 4A) and LLC cells (Fig. 4B). The results showed that NPS significantly inhibited tumor cell proliferation compared to the control group. To investigate the potential mechanisms by which NPS promotes tumor cell apoptosis and inhibits tumor growth, we analyzed the cell cycle of NPS treated A549 and LLC cells by flow cytometry (Fig. 4C, D). The results showed that NPS and PTX effectively arrested the cell cycle of LLC and A549 cells at the G2/M phase, and PTX was slightly less efficient than NPS in cell cycle inhibition. Furthermore, flow cytometric analysis of ROS levels in A549 (Fig. 4E) and LLC cells (Fig. 4F) revealed that NPS significantly increased intracellular ROS levels in tumor cells, which were substantially higher than those in the La and PTX groups, whereas no significant increase in ROS levels was observed in L929 fibroblasts (Figure S3). These results further suggest that La₂O₃@PDA/PTX nanomaterials exert antitumor effects by suppressing cell proliferation, inducing cell cycle arrest, and increasing intracellular ROS levels. La₂O₃@PDA/PTX suppresses tumor cell proliferation, induces cell cycle arrest, and elevates intracellular ROS levels. (A) EdU staining images and statistical analysis of A549 cells with NPS treatment for 24 h. (B) EdU staining images and statistical analysis of LLC cells with NPS treatment for 24 h. (C) Cell cycle images of A549 and LLC cells treated with NPS for 24 h and analysis of the cell cycle phases affected by NPS (D). (E) Intracellular ROS images and statistical analysis of A549 cells with 24 h NPS treatment. (F) Intracellular ROS images and statistical analysis of LLC cells with 24 h NPS treatment. (n = 3) *P < 0.05,**P < 0.01, ***P < 0.001, ****P < 0.0001 RNA-seq reveals that La₂O₃@PDA/PTX inhibits tumor growth through proliferation, apoptosis, TNF signaling and other key pathways To investigate the underlying mechanism of La₂O₃@PDA/PTX, we selected LLC cells for further study and performed the genome-wide RNA-Seq on the LLC cells treated with PBS or NPS. A total of 11,732 genes were detected at the transcriptional level. Among them, 384 genes were transcribed only in the PBS treatment cells, while 349 genes were transcribed only in the cells treated with NPS (Fig. 5A). Compared with the PBS group, 209 genes were upregulated and 246 genes were downregulated following NPS treatment (Fig. 5B). Furthermore, several biological processes were enriched in NPS-treated LLC cells, including regulation of IκB kinase/NF-κB signaling, mitotic cell-cycle phase transition, cell-cycle G2/M phase transition, G2/M transition of the mitotic cell cycle, negative regulation of DNA metabolic process, and regulation of chromosome organization (Fig. 5C and Figure S4). These pathways are known to play critical roles in cell proliferation, apoptosis, cell cycle regulation, DNA damage, and oxidative stress. Collectively, these findings suggest that NPS may inhibit tumor growth by inducing cell cycle arrest, increasing intracellular ROS levels, and causing DNA damage, thereby suppressing proliferation related genes and promoting the expression of apoptosis related genes. Gene Ontology (GO) analysis further indicated the enrichment of biological processes associated with lipid metabolic regulation, mesenchymal development, and growth factor activity in NPS treated LLC cells (Fig. 5D). Similarly, the TNF signaling pathway, the NF-κB signaling pathway, the IL-17 signaling pathway and the ECM-receptor interaction pathway were found to be enriched in cells treated with NPS by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis (Fig. 5E). RNA-seq analysis of LLC cells treated with PBS, La₂O₃@PDA/PTX. (A) A Venn diagram revealed the number of genes transcribed in each treatment group. (B) Volcano plots displayed the differentially expressed genes. (C) GSEA analysis showed that gene sets of the mitotic cell cycle phase transition pathway and the regulation of IκB kinase/NF-κB signaling pathway were enriched in cells treated with NPS. (D) GO and KEGG (E) analysis of differentially expressed genes between cells treated with PBS and those treated with NPS. (F) Heat map of gene expressions in cells treated with PBS and NPS Comprehensive analysis of the RNA-seq data suggested that, in addition to the classical PTX mediated regulation of the cell cycle and apoptosis, La₂O₃@PDA/PTX may further enhance its antitumor efficacy through modulation of TNF/NF-κB associated signaling. TNF/NF-κB associated signaling is involved in the regulation of cell proliferation and apoptosis, and may also influence tumor microenvironment related responses and the expression of genes associated with tumor growth and survival. Further investigation of gene expression changes in LLC cells after NPS treatment revealed a significant downregulation of genes associated with the TNF signaling pathway, including PTGS2, MMP9, VCAM1, LIF, and several chemokines such as CCL2 and CCL20. These expression changes may be associated with increased apoptosis, reduced tumor cell proliferation, and altered immune related responses. Additionally, changes in the expression of cell proliferation and apoptosis related genes further supported this hypothesis, as evidenced by the downregulation of the proliferation marker Ki-67 and the anti-apoptotic gene Bcl-2, alongside the upregulation of the pro-apoptotic gene Bax (Fig. 5F). Collectively, RNA-seq identified NPS induced transcriptional changes and provided insight into the potential mechanisms underlying its antitumor effects. These findings provided a basis for subsequent experimental validation. La₂O₃@PDA/PTX regulates TNF signaling pathway and affects proliferation and apoptosis related gene expression Based on RNA-Seq, we hypothesized that La₂O₃@PDA/PTX enhances the anti-tumor effects of PTX by activating the TNF signaling pathway, inhibiting tumor cell proliferation, and promoting apoptosis (Fig. 6A). To confirm this hypothesis, we performed RT-qPCR to analyze the expression levels of TNF related genes (Ptgs2, Vcam1, MMP9, Lif, Rhbdf2, Cxcl1, Ccl20, Cxcl2, Ccl2), as well as tumor proliferation and apoptosis related genes (Ki67, Bcl2, and Bax) in LLC cells treated with NPS for 24 h (Fig. 6B). The results demonstrated that the expression of TNF related genes and tumor proliferation and apoptosis related genes (Ki67, Bcl2) in NPS treated LLC cells were lower than in the untreated group, while the expression of Bax was higher (Fig. 6C). These results are consistent with our previous findings, suggesting that NPS may regulate the TNF signaling pathway and influence the expression of genes involved in tumor proliferation and apoptosis. Western blot analysis further confirmed these findings, showing lower expression of TNF signaling pathway related proteins (Ptgs2, Mmp9, Vcam1, and LIF) in the NPS treated group. Additionally, Bcl2 expression decreased, while Bax expression increased (Fig. 6D, S6A-F). To provide more direct evidence of NF-κB associated signaling, we further examined phospho-NF-κB p65 (p-p65), total p65, and IκBα. NPS treatment increased p-p65 expression and the p-p65/p65 ratio without significantly altering total p65 expression. IκBα expression was also increased following NPS treatment (Fig. 6D and Figure S5). These results indicated enhanced p65 phosphorylation accompanied by altered IκBα expression, further supporting the modulation of NF-κB associated signaling by NPS. Immunofluorescence staining confirmed the changes in Ki67 (Fig. 6E, S6G), Bcl2 (Fig. 6F, S6H), and Bax (Fig. 6G, S6I) expression. Collectively, these results suggest that NPS modulates TNF/NF-κB associated signaling and alters proliferation and apoptosis related factors, thereby contributing to its antitumor effects. La₂O₃@PDA/PTX modulates TNF/NF-κB associated signaling and proliferation and apoptosis related factors in LLC cells. (A) Schematic illustration of the proposed effects of NPS on TNF/NF-κB associated signaling, tumor-cell proliferation, and apoptosis. (B) RT-qPCR analysis of Ptgs2, Vcam1, Mmp9, Lif, Rhbdf2, Cxcl1, Ccl20, Cxcl2, and Ccl2 expression in LLC cells after 24 h of NPS treatment. (C) RT-qPCR analysis of the proliferation and apoptosis related genes Ki67, Bcl2, and Bax. (D) Representative western blots of Vcam1, Ptgs2, Lif, MMP9, Bax, Bcl2, phospho-NF-κB p65 (p-p65), total p65, and IκBα, with β-actin as the loading control. (E–G) Representative immunofluorescence images of Ki67 (E), Bcl2 (F), and Bax (G).*P < 0.05, ***P < 0.001, ****P < 0.0001 La₂O₃@PDA/PTX inhibited the progression of subcutaneous tumors in mice To evaluate the effect of La₂O₃@PDA/PTX on tumor therapy in vivo, mice with subcutaneous tumors prepared from LLC cells were randomly divided into the PBS group (injected with PBS), the NPS group (injected with La₂O₃@PDA/PTX), the PTX group (injected with PTX), and the La group (injected with La2O3). The timeline of the animal experiment was shown in Fig. 7A. After four intravenous injections of NPS at 2-day intervals, blood and tumor samples were collected from the mice. Body weight and tumor volume were measured before the first injection and prior to each subsequent injection, and tumor weight was recorded after sacrifice. The results indicated that NPS could effectively inhibit tumor growth (Fig. 7B–D). And compared with PBS group, continuous administration of NPS did not affect the weight of mice (Fig. 7E). The result of H&E staining (Fig. 7F) showed that the cancer cell density in NPS group decreased significantly compared with the control groups (PBS, La and PTX group). This suggested that NPS could inhibit the proliferation of tumor cells and induce tumor cell cytotoxicity. To evaluate ROS-associated oxidative damage in vivo, we performed immunohistochemical staining for 4-HNE and 8-OHdG. The NPS group showed increased 4-HNE and 8-OHdG staining compared with the PBS group, supporting enhanced lipid peroxidation and oxidative DNA damage in tumor tissues (Fig. 7G, S7 A-B). To further investigate the mechanism by which NPS inhibited tumor growth, we performed immunohistochemistry to assess the expression of factors associated with TNF/NF-κB related responses, including PTGS2, MMP9, VCAM1, and LIF. The results showed a significant decrease in the expression of these proteins in the NPS group (Fig. 7H), which was consistent with the RNA-seq and cellular experimental results. These findings suggest that NPS effectively inhibits subcutaneous tumor growth and that its therapeutic effect is accompanied by enhanced ROS associated oxidative damage and modulation of TNF/NF-κB associated signaling. La₂O₃@PDA/PTX inhibited the progression of subcutaneous tumors in mice. (A) Timeline of animal experiment. (B) Tumor anatomical size. (C) Weight statistics of tumor tissue on day 8. (D) Tumor volume during administration. (E) Mice body weight during administration. (F) The H&E staining of tumor tissue. (G) Immunohistochemical staining of 4-HNE and 8-OHdG, representing lipid peroxidation and oxidative DNA damage, respectively, in tumor tissues. (H) Immunohistochemical staining of PTGS2, MMP9, VCAM1, and LIF in tumor tissues. **P < 0.01, ***P < 0.001, ****P < 0.0001(n = 6) La₂O₃@PDA/PTX mediated tumor killing associated with T-cell associated signals To further investigate the therapeutic effect of NPS on tumors and its potential association with TNF/NF-κB related responses, we collected mouse serum and measured the levels of several cytokines by ELISA, including TNF-α, IL-10, IFN-γ and IL-12 (Fig. 8A). The results showed that after NPS treatment, the level of TNF-α was significantly increased, while the levels of IFN-γ and IL-10 were significantly decreased, and no significant difference was observed in the level of IL-12. To investigate the effect of NPS on T-cell associated signals, we performed multiplex immunofluorescence staining. The results showed that, compared to the control group, the expression levels of CD4, CD8, and CD3 were significantly elevated in the NPS group (Fig. 8B, S7C), suggesting that NPS may promote T cell infiltration and enhance T cell cytotoxicity against tumor cells. These findings are consistent with the ELISA results, as the changes in TNF-α and IL-10 levels indicate that NPS treatment may shift the tumor microenvironment toward a pro-inflammatory, immune-activated state. The levels of IFN-γ and IL-12 may not have reached their peak at the time of measurement. Quantitative analysis of the immunofluorescence data revealed that, compared to the PBS group, the La group did not show a significant increase in CD3 and CD8 levels, whereas the PTX group showed a more pronounced increase. This suggests that the ability of NPS to modulate T cell activity may be linked to PTX, with La and PDA possibly providing a supportive enhancing effect. La₂O₃@PDA/PTX modulates cytokine expression, promotes T cell infiltration, and regulates the expression of tumor proliferation and apoptosis related proteins. (A) Cytokine levels of TNF-α, IL-10, IL-12 and IFN-γ in mouse serum. (B) Multiplex fluorescence staining technique of CD3, CD4, and CD8 expression in tumor tissues. Immunohistochemistry results of Bax (C), cMyc (D) and Cyclin D1 (E) in tumor tissues. Immunofluorescence results of Ki67 (F) and Bcl2 (G) in tumor tissues. (ns stands for no significant difference). * P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (n = 4) In addition to immune infiltration, we also analyzed the expression of cell cycle, tumor proliferation, and apoptosis related proteins (C-myc, Cyclin-D1, Bax, Ki67, and Bcl2) using immunohistochemistry and immunofluorescence (Fig. 8C–G and Figure S7D–H). The results demonstrated that compared to the control groups, NPS indeed effectively inhibited the expression of Ki67 and Bcl2, while increasing the expression of the pro-apoptotic protein Bax. Although the expression of C-myc in NPS group was slightly higher than that in PTX and La groups, and the expression of cyclin D1 was slightly higher than that in La group, it was still significantly lower than that in the PBS group, which may be related to PDA. These findings suggest that NPS modulates cytokine profiles and TNF/NF-κB associated signaling, accompanied by changes in T-cell associated signals and proliferation and apoptosis related proteins. Meanwhile, the changes in cell-cycle, proliferation, and apoptosis related proteins were consistent with the established antitumor effects of PTX. La₂O₃@PDA/PTX inhibits tumor progression in a lung metastasis model Lung metastasis models were prepared by injecting 8 × 10⁵ Luc-MC38 cells per mouse into the tail vein of C57BL/6 mice. On day 5 after cell injection, pulmonary metastasis was confirmed by bioluminescence imaging, after which the mice were divided into two groups (six mice per group) to monitor the lung metastasis process. Figure 9A and B showed the construction of Luc-MC38 cells and the experimental timeline for the lung metastasis model. From day 5, PBS or NPS was intravenously injected every two days for a total of four injections until day 13. D-luciferin potassium salt was administered on days 5, 9, and 13 to monitor pulmonary metastasis by bioluminescence imaging. The results showed that the baseline signals were comparable between the two groups on day 5, whereas the NPS group exhibited significantly lower pulmonary bioluminescence signals on days 9 and 13 (Fig. 9C, D). Besides, mice in the PBS group showed a more rapid weight loss and more severe cachexia compared to the NPS group (Fig. 9H). However, no significant differences in lung or liver weight were observed between the two groups (Figure S10A, B). Representative gross lung images are shown in Fig. 9E. H&E staining showed more extensive pulmonary metastasis in the PBS group than in the NPS group (Fig. 9F). Metastatic burden was further quantified as the metastatic tumor area relative to the total lung tissue area, and this proportion was significantly lower in the NPS group (Fig. 9G). Immunofluorescence and immunohistochemistry results of lung tumor tissues revealed that the expression levels of Bcl2, Ki67, c-Myc, and Cyclin D1 in the NPS group were lower than those in the PBS group, while the expression of Bax was higher (Fig. 9I, J and Figure S9C–G). These findings suggest that NPS effectively inhibits pulmonary metastatic progression. La₂O₃@PDA/PTX inhibits tumor progression in a pulmonary metastasis model. (A) Schematic illustration of the generation of luciferase labeled MC38 cells (Luc-MC38). (B) Experimental timeline of Luc-MC38 inoculation, NPS administration, bioluminescence imaging, and sample collection. (C) Longitudinal bioluminescence images of mice in the control and NPS groups on days 5, 9, and 13. (D) Quantification of pulmonary bioluminescence radiance. (E) Gross lung images from all mice in each group. (F) Representative whole lung H&E-stained sections and enlarged images of metastatic lesions. (G) Quantification of metastatic tumor area relative to the total lung tissue area. (H) Mouse body weight changes during treatment. (I) Immunohistochemical staining of c-Myc, Cyclin D1, and Bax in lung tumor tissues. (J) Immunofluorescence staining of Bcl2 and Ki67 in lung tumor tissues. ns, not significant; *P < 0.05, **P < 0.01, and ****P < 0.0001 (n = 6) La₂O₃@PDA/PTX demonstrates excellent biocompatibility in vivo Although NPS showed favorable cytocompatibility in vitro, its in vivo safety was further evaluated during tumor treatment. Following four intravenous administrations of PBS, La₂O₃, PTX, or NPS at 2-day intervals, blood and major organs, including the heart, liver, spleen, lung, and kidney, were collected for safety assessment. H&E staining revealed no obvious histopathological abnormalities in the major organs of the treatment groups compared with the PBS group (Figure S9A). Routine hematological parameters also showed no significant differences among the groups (Figure S9B). Furthermore, serum biochemical analysis showed no significant differences in ALT, AST, BUN, or creatinine between the control and NPS groups (Figure S8), indicating no detectable impairment of hepatic or renal function. Collectively, these results suggest that NPS did not cause detectable short term systemic toxicity at the tested dose and observation period. Discussion PTX is a representative chemotherapeutic agent that is widely used in the treatment of lung cancer, breast cancer, pancreatic cancer, and other types of cancer. It specifically binds to β-tubulin, thereby disrupting mitosis and inducing tumor-cell apoptosis. However, its clinical utility is limited by poor water solubility and systemic toxicity. To address these issues, researchers have extensively explored nanocarriers, such as liposomes and gold nanoparticles, to enhance drug delivery efficiency and minimize adverse effects. However, existing nanoparticle-based PTX formulations may still be limited by low drug utilization and off-target toxicity. In this study, we successfully developed a La₂O₃-based nanodrug, La₂O₃@PDA/PTX, in which PTX was loaded onto the PDA coating through non-covalent interactions. Our results demonstrated that, compared with free PTX, La₂O₃@PDA/PTX exhibited improved aqueous dispersibility and safety and effectively inhibited tumor-cell migration and proliferation while promoting apoptosis. The incorporation of La₂O₃ contributed to the enhancement of intracellular ROS levels and ROS associated oxidative damage in tumor cells. Additionally, like PTX, La₂O₃@PDA/PTX induced G2/M cell-cycle arrest, leading to apoptosis. Mechanistically, La₂O₃@PDA/PTX not only affected mitosis and cell-cycle progression but also modulated TNF/NF-κB associated signaling, accompanied by changes in cytokine levels and T-cell-associated immunofluorescence signals, which is consistent with previous studies on paclitaxel [47]. Additionally, La₂O₃ nanoparticles and PDA may enhance these effects. Furthermore, the nanodrug downregulated the proliferation and anti-apoptotic proteins Ki67 and Bcl-2 while upregulating the pro-apoptotic protein Bax, thereby contributing to tumor growth inhibition. Importantly, the safety assessments of La₂O₃@PDA/PTX revealed no significant adverse effects on peripheral blood parameters, hepatic or renal function, or the histological structures of major organs. It also exhibited favorable hemocompatibility. These findings suggest that La₂O₃@PDA/PTX is a promising and relatively safe candidate for tumor therapy. Although La₂O₃@PDA/PTX integrates the ROS enhancing effects of La₂O₃ with PTX mediated chemotherapy and has demonstrated promising antitumor activity, several limitations require further investigation. First, although the safety of La₂O₃ nanoparticles and La₂O₃@PDA/PTX in tumor therapy has been preliminarily investigated, the long-term biosafety of La₂O₃@PDA/PTX should be evaluated over extended observation periods. Second, although the current nanoplatform showed therapeutic efficacy, PTX loading was accompanied by some nanoparticle aggregation and an increase in particle size, which may affect its stability and biological performance. Additionally, the inhibitory effect in the MC38 derived model was somewhat weaker than that observed in the LLC lung cancer models. Addressing these issues will be important for the potential clinical translation of La₂O₃@PDA/PTX as a nanotherapeutic platform for malignant tumors. Supplementary Information Supplementary material 1. Acknowledgements The picture materials in the schematic diagram are provided by “BioRender.com”. Author contributions Conceptualization: Long Zhang; Data curation: Cai Zhang, Long Zhang, Jing Tian, Shuanying Yang and Jie Shi; Formal analysis: All authors; Funding acquisition: Shuanying Yang and Long Zhang; Investigation: Cai Zhang, Bo Yuan, Lizhong Zeng, Xiao Li, Umid Sunnatovich Mamedov, Laziz Nurkhonovich Niyazov, Yuanyuan Cheng, Tong Jiao, Xin Zhao; Methodology: Long Zhang and Shuanying Yang; Project administration: Shuanying Yang and Long Zhang; Resources: All authors; Software: Cai Zhang and Jing Tian; Supervision: Shuanying Yang; Validation: All authors; Visualization: Cai Zhang and Long Zhang; Roles/Writing – original draft: Cai Zhang and Long Zhang; Writing – review & editing: All authors. Funding This research was financially supported by funds from the National Natural Science Foundation of China (no. 82403050, 82574413 and 82303747), Xi’an Science and Technology Program (24YXYJ0168), Shaanxi Provincial Natural Science Foundation Youth Program (2024JC-YBQN-0803), and Sanqin Scholar Innovation Team Support Program (2022SRCB13-02). Data availability The data that support the plots within this paper and other findings of this study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Cai Zhang and Long Zhang contributed equally to this work. Contributor Information Long Zhang, Email: longzhang@xjtu.edu.cn. Shuanying Yang, Email: yangshuanying@xjtu.edu.cn. References Associated Data Supplementary Materials Supplementary material 1. Data Availability Statement The data that support the plots within this paper and other findings of this study are available from the corresponding author upon reasonable request.